EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immunotherapy in Melanoma: Recent Advances and Future Directions

Andrew Knight, Lilit Karapetyan, John M Kirkwood iD

Cancers · 09.02.2023 · 15 (4) · 1106

DOI: 10.3390/cancers15041106 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 09.02.2023. Verfasst von Andrew Knight und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of General Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA. Die Arbeit wurde bisher 265-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of immunotherapy in the treatment of advanced and high-risk melanoma has led to a striking improvement in outcomes. Although the incidence of melanoma has continued to rise, median survival has improved from approximately 6 months to nearly 6 years for patients with advanced inoperable stage IV disease. Recent understanding of the tumor microenvironment and its interplay with the immune system has led to the explosive development of novel immunotherapy treatments. Since the approval of the therapeutic cytokines interleukin-2 and interferon alfa-2 in the 1990s, the development of novel immune checkpoint inhibitors (ICIs), oncolytic virus therapy, and modulators of the tumor microenvironment have given way to a new era in melanoma treatment. Monoclonal antibodies directed at programmed cell death protein 1 receptor (PD-1) and its ligand (PDL-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and lymphocyte-activation gene 3 (LAG-3) have provided robust activation of the adaptive immune system, restoring immune surveillance leading to host tumor recognition and destruction. Multiple other immunomodulatory therapeutics are under investigation to overcome resistance to ICI therapy, including the toll-like receptor-9 (TLR-9) and 7/8 (TLR-7/8) agonists, stimulator of interferon genes (STING) agonists, and fecal microbiota transplantation. In this review, we focus on the recent advances in immunotherapy for the treatment of melanoma and provide an update on novel therapies currently under investigation.

Schlagwörter

Stichwörter der Autor:innen

LAG-3STINGT-VECTLR-9adoptive cell therapyfecal microbiota transplantimmune checkpoint blockadeimmunotherapymelanoma

Autor:innen und Institutionen

  • Department of Medicine, Division of General Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
  • Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
  • Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA 15213, USA.
  • Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA.

ORCID-Profile: John M Kirkwood

Zitieren

APA

Knight, A., Karapetyan, L., & Kirkwood, J. M. (2023). Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers, 15(4), 1106. https://doi.org/10.3390/cancers15041106

Vancouver

Knight A, Karapetyan L, Kirkwood JM. Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers. 2023;15(4):1106. doi:10.3390/cancers15041106

BibTeX
@article{Knight2023,
  author = {Knight, Andrew and Karapetyan, Lilit and Kirkwood, John M},
  title = {Immunotherapy in Melanoma: Recent Advances and Future Directions},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {4},
  pages = {1106},
  doi = {10.3390/cancers15041106}
}
Kostenlos starten →